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ABSTRACT
Graft-versus-host disease (GVHD) causes significant morbidity and mortality in patients undergoing allogeneic bone
marrow transplantation following either a conventional or reduced-intensity preparative regimen. In a murine model,
inactivation of host dendritic cells (DCs) was associated with a significant reduction in acute GVHD, suggesting that
host DCs may play an important role in the pathogenesis of acute GVHD. The role of host DCs in the development
of GVHD following allogeneic stem cell transplantation in humans, however, is unclear. We examined DC chimerism
in patients with various hematologic malignancies who underwent a reduced-intensity preparative regimen of
extracorporeal photophoresis, pentostatin, and reduced-dose total body irradiation (n  21) or a conventional
preparative regimen of cyclophosphamide and total body irradiation (n 3). Full donor hematopoietic reconstitution
was demonstrated in 19 of 21 patients who underwent a reduced-intensity preparative regimen and in all patients who
underwent a conventional preparative regimen. Grade 0 to I acute GVHD and limited or no chronic GVHD were
observed in 18 patients who underwent a reduced-intensity regimen and 1 patient who underwent a conventional
regimen who achieved full donor DC chimerism at day 100 posttransplantation. In contrast, grade II to IV acute
GVHD and extensive chronic GVHD were observed in the 2 patients who underwent a conventional regimen and the
1 patient who underwent a reduced-intensity regimen who had host rather than donor DC chimerism. The
persistence of host DCs at day 100 posttransplantation is correlated with the development of severe acute and
chronic GVHD (P  .001). Host DCs may represent a therapeutic target for reducing GVHD in allogeneic bone
marrow transplants.
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INTRODUCTION
High-dose chemotherapy and radiation followed by alloge-
neic transplantation with hematopoietic stem cells have been
used successfully to treat many hematologic malignancies [1].
The power of donor T cells to generate a graft-versus-malig-
nancy effect is evident in the lower rates of relapse among
non–T-cell-depleted transplant regimens [2] and in the ability
for donor lymphocyte infusions to induce complete remissions
following disease relapse [3]. Allogeneic transplantation, how-
ever, also is associated with the development of graft-versus-host
disease (GVHD) where donor T-cell activation stimulates cy-
tokine responses that damage host skin, liver, and gastrointes-
tinal tract tissues [4]. Recently, reduced-intensity preparative
regimens have been developed using reduced doses of chemo-
therapy and radiation in an attempt to reduce regimen-related
toxicity [5-12]. Although successful donor engraftment has been
achieved with minimal regimen-related toxicity in older patients
with comorbidities that exclude them from a conventional trans-
plantation, GVHD continues to cause substantial morbidity and
mortality in up to 50% of patients [5,6,8].
The immunopathophysiology of acute GVHD (aGVHD)
begins when the preparative regimen damages host tissues [13].
Host dendritic cells (DCs) process and present host-antigens to
donor T cells, resulting in activation and release of pro-inﬂam-
matory cytokines that initiate GVHD [14]. Current treatments
for GVHD include immunosuppression with cyclosporine,
methotrexate, mycophenolate mofetil, and corticosteroids
[15,16]. Standard GVHD therapy, however, still results in sub-
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stantial morbidity and mortality [17]. Donor T-cell depletion
prior to transplantation reduces the incidence of GVHD at the
expense of increased engraftment failure, opportunistic infec-
tions, and disease relapse [18]. Both approaches have been lim-
ited by the inability to suppress donor T cells responsible for
GVHD without suppressing donor T cells responsible for a
graft-versus-malignancy effect.
In a murine model, inactivating host DCs prevented acti-
vation of donor T cells and the development of GVHD, sug-
gesting that host DCs play a role in the development of GVHD
[19]. Although engraftment of donor DCs has been demon-
strated in human transplants [20], the relationship between host
DCs and GVHD remains unknown. We, therefore, examined
the association between DC chimerism posttransplantation and
the development of aGVHD and chronic GVHD in patients
following allogeneic bone marrow transplantation.
PATIENTS, MATERIALS, AND METHODS
Transplantation Preparative Regimens
Patients requiring a reduced-intensity preparative regimen
because of advanced age or comorbidities received extracorpo-
real photophoresis (ECP) on days –7 and -6, pentostatin of 4
mg/m2 by continuous infusion on days –5 and -4, and total body
irradiation of 600 cGy in 3 fractions on days –3 and -2. Patients
eligible for a conventional preparative regimen received cyclo-
phosphamide of 60 mg/kg on days –5 and -4, followed by total
body irradiation of 1,200 cGy in 6 fractions on days -3, -2, and
-1. Both groups of patients received unmanipulated hematopoi-
etic stem cell infusion on day 0.
Supportive Care
GVHD prophylaxis for both groups consisted of cyclospor-
ine A (CsA) 2.5 mg/kg/d by continuous infusion starting on day
-1 and converted to oral CsA when tolerated with methotrexate
of 15 mg/m2 on day1, and 10 mg/m2 on day3 [15]. CsA was
tapered off on day 100 and patients were maintained on
mycophenolate mofetil of 500 mg orally twice a day for 1 year.
Methylprednisolone of 1 mg/kg was used for treatment of
GVHD and was tapered off when GVHD symptoms disap-
peared.
Anti-microbial prophylaxes for both groups were performed
according to institutional protocols. These included tre-
methoprim-sulfamethoxazole for Pneumocystis carinii prophy-
laxis, valacyclovir for herpes simplex virus prophylaxis, and ﬂu-
conazole for fungal prophylaxis.
Blood Samples
Whole blood was collected from donors at baseline and
from patients at baseline, time of engraftment, and day 100
posttransplantation. Mononuclear cells were isolated following
Ficoll (Pharmacia Biotech, Wikstro¨m, Sweden) separation.
DC Growth
To induce DC differentiation, mononuclear cells at day
100 posttransplantation were cultured in 12 well plates
(Costar, Cambridge, MA) at 5  105 cells in AIM V medium
(Gibco BRL, Grand Island, NY) supplemented with 3% heat-
inactivated human AB serum (Gibco BRL). On day 1, 1,000
IU/mL of interleukin (IL)-4 (R&D Systems, Minneapolis, MN)
and 1,000 IU/mL of granulocyte-macrophage colony stimulat-
ing factor (R&D Systems) were added to each well and incu-
bated in 5% CO2 at 37° C for 2 days. DCs were pulsed with 0.01
Lf/mL of tetanus toxoid (R&D Systems) on day 3. After washing
off cells and restoring the medium, 20 ng/mL of tumor necrosis
factor–alpha (R&D Systems) was added to the medium on days
4 and 5. DCs were stimulated with 10 ng/mL of phorbol my-
ristate acetate (R&D Systems) on day 6 and collected on day 8.
DCs were identiﬁed with either phycoerythrin or ﬂuorescein
isothiocyanate-conjugated monoclonal antibodies to CD80,
CD123, CD83, and CD86(Becton Dickinson, Mountain
View, CA) and were measured using a ﬂuorescence-activated
cell-sorter scanner ﬂow cytometer to determine DC yield.
Chimerism
DNA was isolated withWizard kit (Promega, Madison, WI)
or DNAzol (Gibco-BRL, Rockville, MD). Polymerase chain
reaction (PCR) using primers to highly polymorphic short tan-
dem repeats (STR) was performed with Geneprint STR III kit
(Promega) according to manufacturer’s instructions on a Per-
kin-Elmer 2400 cycler (Woburn, MA). Products were run on a
6% polyacrylamide gel, labeled with ethidium bromide, and
visualized under ultraviolet light. For sex-mismatched patients,
ﬂuorescent in situ hybridization using a Y-chromosome probe
was used to determine chimerism.
Endpoints
The primary endpoint was correlation of DC chimerism
with incidence and severity of aGVHD and chronic GVHD as
graded by standard criteria [21,22]. Severe GVHD was deﬁned
as grade II to IV acute GVHD or extensive chronic GVHD.
Disease relapse was deﬁned using standard morphologic criteria.
Statistics
Progression-free survival and overall survival were esti-
mated using the Kaplan-Meier method. Correlations were de-
termined to be signiﬁcant if a P value  .05 was obtained using
chi-square tests.
RESULTS
Patient Characteristics
Twenty-one patients who underwent an ECP-pentostatin–
based preparative regimen and 3 patients who underwent a
conventional preparative regimen were evaluable for DC chi-
merism (Table 1). In the ECP group, the median age was 49
years (range, 19-70 years). Indications for transplantation were
as follows: 4 patients with acute myelogenous leukemia; 4 pa-
tients with chronic myelogenous leukemia; 4 patients with my-
elodysplastic syndrome; 3 patients with non-Hodgkin’s lym-
phoma; 2 patients with myeloﬁbrosis; and 1 patient each with
chronic lymphocytic leukemia, multiple myeloma, Hodgkin’s
disease, and renal cell carcinoma. Risk factors for GVHD in-
cluded the following: 3 with 5/6 HLA sibling-matched donors;
2 with 6/6 HLA-matched unrelated donors; 10 aged older than
50 years; 6 from female donors; 8 with cytomegalovirus sero-
positivity; 4 with previous autologous bone marrow transplan-
tations. Of the 3 patients who underwent a conventional pre-
parative regimen, 1 patient with chronic myelogenous leukemia
had a 6/6 HLA-matched unrelated donors and 2 patients with
acute myelogenous leukemia received marrow grafts from 6/6
HLA-matched siblings. All 3 donors were sex-matched.
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Clinical Outcomes
The median follow-up for patients in the ECP-based pre-
parative regimen was 397 days (range, 164-822 days). Eighteen
of 21 patients achieved full donor mononuclear cell and T-cell
chimerism as measured using STR at time of engraftment (me-
dian, 19 days; range, 9-39 days) without the assistance of donor
lymphocyte infusions, whereas 1 patient required 91 days to
achieve full donor T-cell chimerism. On day 100 posttrans-
plantation, all 19 patients who engrafted had full donor mono-
nuclear cell chimerism by STR. Two patients did not have
donor engraftment and developed full autologous hematopoietic
reconstitution with full host mononuclear cell chimerism by
STR at engraftment and at day 100 posttransplantation. No
patient died prior to day 100. Eighteen of 19 patients (95%)
had grade 0 or I acute GVHD and limited skin or no extensive
chronic GVHD (Table 1). One patient developed grade II acute
GVHD and extensive chronic GVHD of the skin and died from
GVHD-related complications on day 249. Twelve patients
(57%) remained alive and in complete remission. Four patients
(19%) experienced disease relapse with 1 patient dying from
disease-related complications. Both patients with autologous
hematopoietic reconstitution died of disease-related complica-
tions.
In the 3 patients who underwent a conventional preparative
regimen, median follow-up was 535 days (range, 404-541 days).
All 3 achieved full donor mononuclear cell and T-cell chimerism
at the time of engraftment (median, 20 days; range, 17-26 days)
and at day 100 posttransplantation. All 3 patients remained in
complete remission at the time of analysis. One patient had no
aGVHD or chronic GVHD and remained alive. One patient
who received marrow from a matched unrelated donor had
grade II acute skin GVHD and extensive chronic GVHD of the
skin and liver, whereas the third patient developed grade IV
acute skin and liver GVHD and extensive chronic GVHD of the
skin and gut. Both patients died from GVHD-related compli-
cations.
DC Chimerism
DCs harvested from peripheral blood at day 100 post-
transplantation were differentiated in vitro. The majority of cells
stained with DCmaturation marker CD86, but 90% of all cells
stained with 1 of 4 DC markers (Figure 1). When chimerism
assays were performed, all 19 patients with grade 0 to I aGVHD
and limited or no chronic GVHD had a complete absence of
host DCs (Figure 2 and Figure 3), indicating that the circulating
DCs were all of donor origin. All 3 patients with severe aGVHD
and extensive chronic GVHD had only host DC bands (Figure
2 and Figure 3), suggesting the persistence of host DCs and the
absence of donor DCs. Two patients who did not have donor
engraftment and had autologous hematopoietic reconstitution
demonstrated only host DC bands at day 100 as expected
(Figure 2). The presence of host DCs posttransplantation was
Table 1. Patient Characteristics and Results
Age/Sex Disease
BMT
Type
Prior
Therapy
T-Cell
Chimerism
aGVHD
Grade
cGVHD
Grade
DC
Chimerism Status
Reduced-intensity preparative regimen
31/M AML 6/6 MUD AutoBMT Full donor 0 LTD Full donor CR/alive
37/M CML 6/6 allo None Full donor Skin I LTD Full donor CR/alive
45/M NHL 6/6 allo AutoBMT Full donor 0 LTD Full donor Relapse/dead
59/M CLL 6/6 allo CHOP/Ara-C Full donor 0 None Full donor CR/dead
42/F MM 6/6 allo Mel/IFN Full donor I None Full donor Relapse/dead
58/M NHL 6/6 allo AutoBMT Full donor I None Full donor CR/dead
58/M MDS 5/6 allo Ida/Ara-C Full donor Skin II Skin EXT Full host CR/dead
55/F CML 6/6 allo IFN/Ara-C Full donor 0 LTD Full donor CR/alive
70/M MDS 6/6 allo None Full donor 0 LTD Full donor CR/alive
46/F AML 6/6 allo Ida/Ara-C Full donor 0 None Full donor CR/alive
51/M MF 6/6 allo None Full donor Skin I LTD Full donor CR/alive
60/M MDS 6/6 allo None Full donor Skin I LTD Full donor CR/alive
32/F AML 6/6 allo MOPP/ABVD Full donor Skin I LTD Full donor CR/alive
40/F AML 6/6 MUD Ida/Ara-C Full host N/A N/A Full host PD/dead
19/F HD 6/6 allo AutoBMT Full donor Skin I None Full donor CR/alive
32/F CML 6/6 allo None Full donor 0 None Full donor CR/alive
60/M NHL 6/6 allo CHOP/ESHAP Full donor Skin I None Full donor Relapse/alive
49/M MF 6/6 allo None Full donor Skin I LTD Full donor Relapse/alive
49/M CML 5/6 allo None Full donor Skin I LTD Full donor CR/alive
61/M MDS 5/6 allo None Full host N/A N/A Full host PD/dead
59/M RCC 6/6 allo Il-2 Full donor Skin I None Full donor CR/alive
Conventional preparative regimen
26/M CML 6/6 MUD None Full donor Skin II Liver EXT Full host CR/dead
34/F AML 6/6 allo Ida/Ara-C Full donor 0 None Full donor CR/alive
19/M AML 6/6 allo Ida/Ara-C Full donor Liver, skin IV Gut EXT Full host CR/dead
BMT indicates bone marrow transplantation; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; DC, dendritic
cell; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic
leukemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; MF, myeloﬁbrosis; HD, Hodgkin’s disease; RCC, renal cell carcinoma; MUD,
matched unrelated donor; allo, related donor; Ara-C, cytarabine; Mel, melphalan; IFN, interferon; Ida, idarubicin; IL-2, interleukin-2; LTD, limited;
EXT, extensive; CR, complete remission; PD, progressive disease.
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signiﬁcantly correlated with the development of severe aGVHD
and chronic GVHD (P  .001) and death (P  .01).
DISCUSSION
The pathophysiology of acute GVHD is complex and in-
volves the presentation of host antigens by host DCs to donor T
cells in the context of major histocompatibility complex mole-
cules to activate CD8 cells and initiate the pro-inﬂammatory
cytokine cascade [13]. In murine studies, inactivation of host
DCs before transplantation abrogated GVHD, suggesting that
host DCs that linger after transplantation may play an important
role in the pathogenesis of acute GVHD [19]. In this study, we
evaluated DC chimerism at day 100 posttransplantation fol-
lowing either a conventional or reduced-intensity preparative
regimen and found a signiﬁcant correlation between the persis-
tence of host DCs and the incidence of severe acute and chronic
GVHD. The persistence of host DCs cannot be explained by
mixed chimerism because the reduced-intensity and conven-
tional preparative regimens are myeloablative. This suggests
that host DCs may play a role in the development of GVHD in
human transplants, providing a potential therapeutic target for
reducing GVHD.
DCs form a complex network of antigen-presenting cells
that play a vital role in the induction of primary immunity as
well as the modulation of tolerance. DCs are the most potent
antigen-presenting cells that are uniquely able to induce primary
immune responses against novel antigens through the rich ex-
pression of costimulatory and adhesion molecules [23]. In hu-
mans, DCs are divided into 2 types: mature DC1s induce TH1
differentiation and cytotoxic T-lymphocyte responses, whereas
mature DC2s induce TH2 differentiation and immune tolerance
[24]. In the setting of allogeneic bone marrow transplantation,
TH1 stimulation by DC1s induces the production of inﬂamma-
tory cytokines like tumor necrosis factor–alpha that causes
GVHD, whereas TH2 stimulation by DC2s inhibits TH1 cyto-
kine production via IL-4 and IL-10 [13]. Furthermore, DCs of
host origin appear to be critical in the stimulation of donor T
cells and the initiation of the cytokine cascade of aGVHD [19].
The engraftment kinetics of DCs in human transplants have
been only recently studied [20]. In another study, 19 patients
who underwent either a myeloablative or nonmyeloablative
transplantation had full donor DC chimerism in concert with
full donor T-cell chimerism by day 100 posttransplantation,
but none of the patients developed severe GVHD so the asso-
ciation between DC chimerism and GVHD was indeterminate
[20]. In our study, we analyzed DC chimerism at day 100
posttransplantation to avoid the possibility of delayed engraft-
ment as the cause of persistence of host DCs. In our patients
without severe GVHD, we similarly observed full donor DC
chimerism along with full donor T-cell reconstitution. In our
patients with severe GVHD, however, host DCs persisted at day
100 posttransplantation despite full donor mononuclear cell
and T-cell chimerism. The dichotomy between T-cell and DC
Figure 1. Dendritic cell (DC) yield by ﬂow cytometry. DCs were differentiated with GM-CSF and IL-4. Shaded area represents cells stained with
DC markers. This ﬁgure of a representative patient shows that DCs are predominantly positive for CD80 or CD86. The mean and standard error
of measurement (SEM) for DC markers of cultured cells from all 24 patients are shown.
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chimerism at day 100 posttransplantation suggests that de-
layed or incomplete engraftment is unlikely to be the cause for
the persistence of host DCs in patients with severe GVHD.
The impact of different preparative regimens on host DCs
has not been fully elucidated. Alemtuzumab (Campath) given
pretransplantation has been shown to deplete circulating host
DCs, resulting in the absence of host DCs and a low incidence
of acute GVHD posttransplantation [25]. The low rate of acute
GVHD, however, also may be related to the effects of in vivo
T-cell depletion by the prolonged half-life of alemtuzumab [26].
In our study, 2 of 3 patients with persistent host DCs and severe
GVHD received a conventional preparative regimen, suggesting
that host DCs were not always eradicated by full-dose chemo-
therapy and radiation. In contrast, severe GVHD occurred in
only 5% of patients following our ECP and pentostatin–based
reduced-intensity preparative regimen. This is lower than the
40% to 60% incidence reported with other purine analog-based
regimens [5,6,8,27]. The use of bone marrow stem cells instead
of peripheral blood progenitors is unlikely to explain our low
incidence of severe GVHD because marrow stem cells are as-
sociated with at least a 40% incidence of severe GVHD follow-
ing a conventional preparative regimen at our institution and in
published studies [4]. Furthermore, our GVHD prophylaxis
regimen is unlikely to explain our low incidence of GVHD
because the same regimen resulted in a 40% incidence of severe
GVHD following a conventional preparative regimen. Thus,
the use of ECP pretransplantation may play a role in reducing
the incidence of severe GVHD.
ECP involves the ex vivo exposure of leukapheresed periph-
eral blood mononuclear cells to ultraviolet A light in the pres-
ence of a DNA-intercalating agent, 8-methoxypsoralen, with
subsequent re-infusion of treated cells. The total number of
lymphocytes treated ex vivo per cycle has been estimated to be
between 5% and 15% of the total circulating lymphocytes, and
the total energy delivered via ultraviolet A light is estimated to
be 2 J/cm2/lymphocyte [28]. In our study of the effects of ECP
in the treatment of steroid-refractory chronic GVHD, we ob-
served a 50% reduction in DC populations following ECP with
a shift from DC1 subtypes that promote pro-inﬂammatory cy-
tokine secretion to the DC2 subtypes associated with immune
tolerance [29]. We speculate that ECP pretransplantationj may
modulate host DCs, resulting in the absence of host DCs post-
transplantation, thereby abrogating the development of severe
GVHD.
The role of host DCs in the pathogenesis of GVHD in
human transplants remains controversial. Absence of host DCs
was observed in patients without GVHD following a preparative
regimen with alemtuzumab but the prolonged half-life of alem-
tuzumab may have provided a component of in vivo T-cell
depletion, resulting in little GVHD [26]. In contrast, Clark et al.
Figure 3. Dendritic cell (DC) chimerism following conventional pre-
parative regimen. Chimerism studies were performed on DCs isolated
with GM-CSF and IL-4 from peripheral blood mononuclear cells col-
lected on day100 post-transplant. DNA PCR band pattern for DCs of
a patient with no GVHD is all donor. The DC band pattern for a patient
with grade IV aGVHD and extensive cGVHD was all host.
Figure 2. Dendritic cell (DC) chimerism following reduced intensity
preparative regimen. Chimerism studies were performed on DCs iso-
lated with GM-CSF and IL-4 from peripheral blood mononuclear cells
collected on day100 post-transplant. DNA PCR band pattern for DCs
of a patient with no GVHD is all donor. The DC band pattern for a
patient with grade II aGVHD and extensive cGVHD was all host. The
DC band pattern for a patient who failed engraftment was also all host.
G.W. Chan et al.
174
demonstrated that chronic GVHD was associated with full do-
nor DC chimerism at 18 months posttransplantation, but the
persistence of host DCs earlier after engraftment remains un-
known [30]. The role of host DCs in the pathogenesis of chronic
GVHD is less clear, although host DCs were observed in our
patients with extensive chronic GVHD. Although we demon-
strated an association between the persistence of host DCs and
severe GVHD with 2 different regimens (reduced intensity and
conventional), further longitudinal studies of DC chimerism at
various intervals posttransplantation are needed to conﬁrm our
results.
In conclusion, although our sample size is small, our ﬁnd-
ings are consistent with other studies that report that early
donor DC reconstitution is associated with the absence of severe
GVHD [20, 25]. We now show that the persistence of host DCs
at day 100 after transplantation is signiﬁcantly correlated with
the development of severe aGVHD and chronic GVHD in
patients following either a conventional or a reduced- intensity
preparative regimen. Further studies evaluating the effects of
preparative regimens on host DCs may lead to novel approaches
to modulate these populations and may potentially impact the
incidence of severe GVHD.
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